Form 4: AVNS Director Boosts Stake via Pre-Arranged Plan

Avanos Medical Director Gary Blackford increased his beneficial ownership of company common stock through two purchase transactions totaling 60,000 shares.

Summary

• Gary Blackford, a Director of Avanos Medical, Inc. (AVNS), acquired a total of 60,000 shares of common stock on August 13, 2025.
• One transaction involved the direct purchase of 20,000 shares at a weighted average price of $10.975 per share, with prices ranging from $10.94 to $11.01.
• The second transaction involved the indirect purchase of 40,000 shares at a weighted average price of $10.995 per share, with prices ranging from $10.98 to $11.04.
• These indirect shares are held in trusts for the benefit of certain immediate family members, with Mr. Blackford serving as co-trustee.
• Following these transactions, Mr. Blackford directly beneficially owns 91,593 shares and indirectly beneficially owns 40,000 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant insider buying by a director, indicating confidence in the company's valuation and future, despite the transaction being part of a pre-arranged 10b5-1 plan.

Positives

• A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
• The acquisition of 60,000 shares represents a significant increase in insider ownership.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the execution of a pre-arranged trading plan.

Management Comments

• The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.
• The Reporting Person disclaims beneficial ownership of shares held in trusts except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

Industry Context

This insider transaction reflects a director's individual investment decision within the healthcare and medical devices industry, which is subject to ongoing innovation, regulatory changes, and market demand for medical products.

Related Party Transactions

• 40,000 shares were purchased indirectly and are held in trusts for the benefit of certain immediate family members of the Reporting Person, with the Reporting Person serving as co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal of management's belief in the company's value, potentially boosting investor confidence.

Key Dates

Recommendation

The significant insider buying by a director, totaling 60,000 shares, suggests strong confidence in Avanos Medical's future performance and valuation. While executed under a 10b5-1 plan, the decision to acquire shares at these price levels by a key insider is a positive indicator for investors.

Keywords

Avanos Medical, AVNS, Insider Buying, Director Stock Purchase, Form 4, SEC Filing, 10b5-1 Plan, Healthcare, Medical Devices